Direct-acting antiviral use is associated with increased survival in hepatitis C-related 27 hepatocellular carcinoma patients. Patients treated with direct-acting antiviral who achieved 28 hepatitis C cure had additionally increased survival versus those treated with direct-acting 29 antiviral who did not achieve hepatitis C cure. This study supports the use of direct-acting 30 antiviral for hepatitis C treatment in hepatocellular carcinoma patients. Abbreviations 53 DAA: Direct-acting antivirals; SVR12: 12-week sustained virologic response; HCC: 54 hepatocellular carcinoma; HCV: hepatitis c virus; OS: median overall survival; AJCC: American 55 Joint Committee on Cancer stage; MELD: Model for end stage liver disease; HR: hazard ratio 4 56 Abstract: 57 Background: To investigate the impact of direct-acting antivirals (DAA) and 12-week sustained 58 viral response (SVR12) in patients with hepatocellular carcinoma (HCC) and chronic hepatitis C 59 virus (HCV) infection. Methods: Retrospective analysis of HCC patients diagnosed from 2005 60 to 2016 at an urban tertiary-care hospital. Kaplan-Meier curves and multivariable Cox 61 proportional hazards models were used to assess survival. Results: 969 patients met inclusion 62 criteria. 478 patients received interventional oncology treatment (catheter-based therapies, 63 ablation or combination locoregional therapies), 141 received supportive care (palliative or no 64 treatment), 125 underwent liver transplantation, 112 had tumor resection and 94 received 65 chemotherapy or radiation as their primary treatment. Median overall survival of the cohort was 66 24.2 months (95% CI: 20.9-27.9). 470 patients had HCV (56%). 123 patients received DAA 67 therapies for HCV (26.2%), 83 of whom achieved SVR12 (68%). HCV-positive and HCV-68 negative patients had similar survival (20.7 months vs 17.4 months, p=0.22). Patients receiving 69 DAA therapy had an overall survival of 71.8 months (CI: 39.5-not reached) vs 11.6 months (CI: 70 9.8-14.5) for patients without DAA therapy (p<0.0001). DAA patients who achieved SVR12 had 71 an overall survival of 75.6 months (CI: 49.2-not reached) vs the non-SVR12 group (26.7 months, 72 CI: 13.7-31.1, p<0.0001). Multivariable analysis revealed AJCC, Child-Pugh Score, MELD, 73 tumor size, tumor location and treatment type had independent influence on survival (p<0.05). 74 In HCV-positive patients, AJCC, MELD, tumor location, treatment allocation and DAA were 75 significant (p<0.05). In patients receiving DAA therapy, only MELD and SVR12 were predictive 76 of overall survival (p<0.05). Conclusions: DAA therapy and achieving SVR12 is associated 77 with increased overall survival in HCV patients with HCC. 78 5 79
Chronic HCV infection is the second most common risk factor for HCC and is 87 responsible for 10-25% of all HCC cases. 1 Over 20-30 years, 20-30% of patients with chronic 88 HCV infections will develop cirrhosis and end stage liver disease and1-4% of these patients will 89 progress to HCC each year. 5, 6 Of all HCV related HCC cases, 80-90% occur in the setting of 90 cirrhosis. 2 With more than 3.5 million patients in the United States and an estimated 130-170 91 million patients worldwide currently infected with HCV, the importance of HCV management in 92 HCC therapeutic care and prevention is clear. 7, 8 The major current therapeutic goal for HCV and 93 prevention of liver disease progression is sustained viral response (SVR), which is defined by 94 negative HCV RNA at 12 weeks post-treatment (SVR12) and appears to be durable with a late 95 virologic relapse rate of less than 1%. 9,10 96 Therapeutic management of HCV has recently undergone a shifted from interferon-based 97 therapies to all-oral interferon-free direct-acting antiviral (DAA) combination regimens. DAAs 98 are a new class of drugs that target nonstructural proteins responsible for replication and 99 infection of the hepatitis c virus. 10, 11, 12 Values were considered statistically significant with a p-value of less than 0.05. Patients with HCC and HCV that received a DAA and achieved sustained viral response 194 (SVR12) (n=83) versus those who did not achieve SVR12 (n=31) (p<0.0001). 1.03 (1.00-1.06, p=0.0168) 1.05 (1.00-1.11, p=0.0468 1.32 (1.03-1.69, p=0.026)  1.62 (1.14-2.30, p=0.0072 Reaching SVR12 is not an easy task in the HCC patient population. 
